Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant

Bone Marrow Transplant. 2000 Oct;26(8):903-5. doi: 10.1038/sj.bmt.1702591.


Herpes simplex virus (HSV) causes serious problems in immuno-compromised patients such as those receiving a bone marrow transplant (BMT) for a hematological malignancy. Resistance to acyclovir (ACV) is a growing major concern. Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach. We describe a girl treated with cidofovir for a life-threatening ACV-resistant HSV infection after an unrelated BMT for a relapse of an acute myeloblastic leukemia (AML).

Publication types

  • Case Reports

MeSH terms

  • Acyclovir / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Bone Marrow Transplantation / adverse effects*
  • Cidofovir
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • Drug Resistance
  • Female
  • Foscarnet / therapeutic use*
  • Herpes Simplex / drug therapy*
  • Humans
  • Infant
  • Organophosphonates*
  • Organophosphorus Compounds / therapeutic use*


  • Antiviral Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Foscarnet
  • Cytosine
  • Cidofovir
  • Acyclovir